| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/17/2004 | WO2004050015A2 Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof |
| 06/17/2004 | WO2004050012A2 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 06/17/2004 | WO2004050011A2 High enantiomeric purity dexanabinol for pharmaceutical copositions |
| 06/17/2004 | WO2004049830A1 Sustained improver of muscular fatigue |
| 06/17/2004 | WO2004043446A3 Combination product for controlling insect pests |
| 06/17/2004 | WO2004039371A3 Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain |
| 06/17/2004 | WO2004039360B1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004037769A3 Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant |
| 06/17/2004 | WO2004034999A3 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 06/17/2004 | WO2004033465B1 2' oxo-voruscharin and derivatives thereof |
| 06/17/2004 | WO2004032911A3 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 06/17/2004 | WO2004031233A9 Novel chemokine-like polypeptides |
| 06/17/2004 | WO2004030685A3 Use of il-2 receptor antibodies to prevent toxicity associated with amphotericin b antimycotic therapy |
| 06/17/2004 | WO2004030611A3 Non-nucleoside reverse transcriptase inhibitors |
| 06/17/2004 | WO2004029204A3 Substituted pyrimidines |
| 06/17/2004 | WO2004028470A3 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 06/17/2004 | WO2004024144A9 Method of treating skin disorders |
| 06/17/2004 | WO2004022152A9 Radiotherapy method using x-rays |
| 06/17/2004 | WO2004022007A8 Composition and method for treating soft nails |
| 06/17/2004 | WO2004021997A3 Inhibitors of fungal invasion |
| 06/17/2004 | WO2004019870A3 Breath freshening and oral cleansing product using salicylaldehyde |
| 06/17/2004 | WO2004018414A3 Antibacterial agents |
| 06/17/2004 | WO2004016256A3 AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
| 06/17/2004 | WO2004014351A3 Use of cgrp antagonist compounds for treatment of psoriasis |
| 06/17/2004 | WO2004014316A3 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 06/17/2004 | WO2004014291A3 Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| 06/17/2004 | WO2004013282A3 Bis (amino acid) molecular scaffolds |
| 06/17/2004 | WO2004012762A3 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 06/17/2004 | WO2004012652A9 Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| 06/17/2004 | WO2004012651A3 Composition for heart disease, method to prepare same and uses thereof |
| 06/17/2004 | WO2004010946A3 Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| 06/17/2004 | WO2004010941A3 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004009023A3 Novel inhibitors of ubiquitin isopeptidases |
| 06/17/2004 | WO2004007742A3 Chromosome 6 and 9 genes involved in premature canities |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2003106660A3 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/17/2004 | WO2003105781A3 Ophthalmic compositions for treating ocular hypertension |
| 06/17/2004 | WO2003102138A3 Elongase genes and uses thereof |
| 06/17/2004 | WO2003101378A3 Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| 06/17/2004 | WO2003097050A3 A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| 06/17/2004 | WO2003071281A3 Estrogen receptor interaction with a transcription factor |
| 06/17/2004 | WO2003070184A3 Sodium channel blockers |
| 06/17/2004 | WO2003063824A3 Pharmaceutical composition |
| 06/17/2004 | WO2003053997A3 Methods of increasing endogenous erythropoietin (epo) |
| 06/17/2004 | WO2003051380A3 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 06/17/2004 | WO2003049668A3 Method of administering calcium citrate |
| 06/17/2004 | WO2003037308A8 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 06/17/2004 | WO2003032810A3 Treatment and diagnosis of insulin resistant states |
| 06/17/2004 | WO2003028700A3 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 06/17/2004 | WO2003026564A9 Pharmaceutical compositions for the treatment of urinary disorders |
| 06/17/2004 | WO2003024972A8 New oripavine derivatives and their uses as medicines |
| 06/17/2004 | WO2003017992A3 Means for treatment of atherosclerosis |
| 06/17/2004 | WO2003015689A3 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 06/17/2004 | US20040117006 Drug delivery from stents |
| 06/17/2004 | US20040116738 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 06/17/2004 | US20040116718 Therapy for breast cancer; plant extracts |
| 06/17/2004 | US20040116715 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 06/17/2004 | US20040116707 4-Pyrrolidino-phenyl-benzyl ether derivatives |
| 06/17/2004 | US20040116706 Therapeutic ureas |
| 06/17/2004 | US20040116703 Central nervous system disorders, nicotinic acetylcholine receptors; endocrine diseases; antiinflammatory agents; analgesics; drug dependency; skin disorders; Alzheimer's and Parkinson's disease |
| 06/17/2004 | US20040116699 Melanocortin receptor agonists |
| 06/17/2004 | US20040116698 6-Substituted pyrido-pyrimidines |
| 06/17/2004 | US20040116697 Novel compounds |
| 06/17/2004 | US20040116695 2-Mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 06/17/2004 | US20040116694 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 06/17/2004 | US20040116689 can comprise DNA, RNA, PNA, or any combination or chimera thereof |
| 06/17/2004 | US20040116636 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 06/17/2004 | US20040116537 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| 06/17/2004 | US20040116535 enantiomers or racemic mixtures of mexiletine, used for prophylaxis of tinnitus |
| 06/17/2004 | US20040116534 Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine |
| 06/17/2004 | US20040116533 Pharmaceutical composition |
| 06/17/2004 | US20040116532 Isomers of 2-[(diphenylmethyl)sulfinyl] acetamide, including excipients such as diluents, binders or lubricants, used for prophylaxis of attention deficit disorder |
| 06/17/2004 | US20040116531 Nonaqueous ointments comprising carbamide dispersed in petrolatum, paraffins and/or microcrystalline wax, used for prophylaxis of skin disorders such as eczema or psoriasis |
| 06/17/2004 | US20040116530 Tissue fibrosis inhibitors |
| 06/17/2004 | US20040116529 Anticancer and chemopreventative agents and methods of use thereof |
| 06/17/2004 | US20040116527 Agents against stress-induced diseases |
| 06/17/2004 | US20040116526 Polymorphic forms of nateglinide |
| 06/17/2004 | US20040116525 Carbocyclic acids and salts such as [(1R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, used as chemical intermediates for drugs used as analgesics, anxiolytic agents, or for prophylaxis of neurodegenerative disorders |
| 06/17/2004 | US20040116524 Method of administering opthalmic fluids |
| 06/17/2004 | US20040116523 Use of c4-c10 acids for preventing gram-negative bacterial infections |
| 06/17/2004 | US20040116522 Medicinal solutions |
| 06/17/2004 | US20040116521 Prophylaxis of fungal infections using mixtures of 2-chloroethanesulfonic acid and salts, water and adjuvants such as buffers, stabilizer agents, flavors or preservatives |
| 06/17/2004 | US20040116520 Anti-stress agents |
| 06/17/2004 | US20040116516 Pharmaceutical composition |
| 06/17/2004 | US20040116514 Carotenoid compounds and vitamin E compounds; preventing progression of hepatic disease such as cirrhosis to hepatic cancer; lycopene, beta -carotene, alpha-carotene, other natural carotenoids, and alpha -tocopherol |
| 06/17/2004 | US20040116512 Natural vitamin E compositions with superior antioxidant potency |
| 06/17/2004 | US20040116511 Jasmonic acid compound, a gibberellic acid compound, a zeatin compound or a combination thereof; promote skin cell renewal, wound healing, and production of fibronectin by fibroblasts |
| 06/17/2004 | US20040116510 hydrochlorothiazide and/or losartan potassium with ezetimibe; preventing or reducing the risk for occurrence of an atherosclerotic disease event in a hypertensive patient |
| 06/17/2004 | US20040116509 Antiviral agent; reducing the activity of viral polymerase; 3-(4-Chloro-2,5-dimethyl-benzenesulfonylamino)-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid for example |
| 06/17/2004 | US20040116508 1-(N,N-bischloroethylaminoethoxy)-4-tert-butyldimethylsilyloxythioxanthone; administering first then sodium fluoride; tissue targeted therapy; administering in nontoxic, protodrug form which accumulates in neoplasm, followed by an activation drug |
| 06/17/2004 | US20040116507 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 06/17/2004 | US20040116506 Use of levetiracetam for treating or preventing acute headaches |
| 06/17/2004 | US20040116505 By administering a pyrrolidone compound such as aniracetam, piracetam, oxiracetam, pramiracetam, nefiracetam, nebracetam, fasoracetam, or levetiracetam; Tourette's syndrome, parkinson's disease for example |
| 06/17/2004 | US20040116502 Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones |
| 06/17/2004 | US20040116501 Treatment of nonallergic rhinitis by selective phosphodiesterase 4 inhibitors |
| 06/17/2004 | US20040116500 Treating berylliosis by administering a porphyrin analogue; packaged dosage forms; inhalants |
| 06/17/2004 | US20040116499 treatment of inflammatory or proliferative diseases of the skin and other organ systems; from yeast of the genus Malassezia; for example, 2,3-dihydro-4,5-bis(indol-3-yl)furan-2,3-dione; against multiresistent staphylococci |
| 06/17/2004 | US20040116498 Regulations of lipids and/or bone density and compositions therefor |
| 06/17/2004 | US20040116497 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 06/17/2004 | US20040116495 Compounds and methods |